New drug combo may let bladder cancer patients keep their bladder

NCT ID NCT07475806

Recruiting now Disease control Sponsor: Astellas Pharma Global Development, Inc. Source: ClinicalTrials.gov ↗

First seen Mar 21, 2026 · Last updated May 16, 2026 · Updated 6 times

Summary

This study tests a combination of two drugs, enfortumab vedotin and pembrolizumab, in people with muscle-invasive bladder cancer. The goal is to see if this treatment can eliminate the cancer and allow patients to keep their bladder instead of having it surgically removed. The study involves 240 adults who are eligible for bladder removal surgery but may benefit from this alternative approach.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MUSCLE-INVASIVE BLADDER CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Accellacare of Duly
RECRUITING

Lisle, Illinois, 60532, United States
Arkansas Urology Associates
RECRUITING

Little Rock, Arkansas, 72211, United States
Centers for Advanced Urology, LLP
RECRUITING

Bala-Cynwyd, Pennsylvania, 19004, United States
Sidney Kimmel Comprehensive Cancer - Asplundh Cancer Pavilion
RECRUITING

Willow Grove, Pennsylvania, 19090, United States
Thomas Jefferson University
RECRUITING

Philadelphia, Pennsylvania, 19107, United States

Conditions

Explore the condition pages connected to this study.

MUSCLE-INVASIVE BLADDER CANCER